Nanexa

3.76 SEK

-2.34 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-2.34 %

+3.44 %

-15.62 %

+124.85 %

+69.14 %

+174.09 %

+0.27 %

-62.83 %

-54.10 %

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Market cap

633.04M SEK

Turnover

433.31K SEK

Revenue

36.15M

EBIT %

-24.26 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

29.4

2026

Interim report Q1'26

12.5

2026

General meeting '26

27.8

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Third party research2/20/2026, 7:41 AM

Nanexa: Funding secured as semaglutide pivot sharpens commercial focus - Emergers

Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to leverage its PharmaShell technology into commercial value creation: the Moderna license development agreement ...

Regulatory press release2/19/2026, 7:01 AM

Nanexa publishes year-end report and Q4 report 2025

Regulatory press release1/27/2026, 7:30 AM

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Third party research12/12/2025, 7:12 AM

Nanexa: First license with Moderna an important validation of PharmaShell - Emergers

The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell platform, as Moderna, a global leader in mRNA therapeutics, commits to test up to five compounds under a structure including USD 3m upfront, up to USD ...

Press release12/12/2025, 7:00 AM

Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell

Regulatory press release12/10/2025, 9:35 PM

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

Third party research11/7/2025, 8:58 AM

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Press release11/7/2025, 7:00 AM

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Regulatory press release11/6/2025, 7:00 AM

Nanexa publishes interim report for January-September 2025

Press release10/16/2025, 6:25 AM

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Regulatory press release10/1/2025, 10:40 AM

Nanexa AB changes Certified Adviser to Tapper Partners AB

Press release9/22/2025, 6:00 AM

Nanexa receives Japanese patent approval for specific PharmaShell structure

Third party research8/28/2025, 6:09 AM

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly liraglutide exposure over 36 days without significant gastrointestinal side effects. The company also gained industry...

Press release8/28/2025, 6:00 AM

Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Regulatory press release8/27/2025, 5:00 AM

Nanexa publishes interim report for January-June 2025

Press release8/8/2025, 8:43 AM

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

Press release6/24/2025, 6:00 AM

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Press release6/3/2025, 1:10 PM

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Press release5/23/2025, 7:15 AM

All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study

Regulatory press release5/15/2025, 1:45 PM

Bulletin from Nanexa’s Annual General Meeting

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.